Overview

Our History

Leadership Team

Partner

Portfolio Advisory Board

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Media

Company News

Aug 12

2026

[NEWS]Hua Medicine Announces First Prescription of Dorzagliatin Dispensed in Hong Kong, China

Hua Medicine ("the Company", HKEX Stock Code: 2552) announced today that dorzagliatin (trade name: MYHOMSIS®, 華領片®), the Company's first-in-class glucosekinase activator (GKA), has been dispensed its first prescription in Hong Kong.

Jul 06

2026

[NEWS] Hua Medicine Enters Research Collaboration Agreement with GemVCare to Generate Real-World Evidence for Dorzagliatin in Hong Kong

Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced today that it has entered a scientific research collaboration agreement with GemVCare (referred to as GVC), a Hong Kong-based biotechnology enterprise. Leveraging their respective core strengths, the two parties will conduct joint clinical trial and real-world research using dorzagliatin (trade name: MYHOMSIS®, 華領片®)

Jun 30

2026

[NEWS] Hua Medicine's Dorzagliatin Approved for Type 2 Diabetes Treatment in Macao SAR, China

Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (trade name in Macao: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Administration Bureau of the Macao Special Administrative Region for the treatment of Type 2 diabetes in adults.

Jun 29

2026

[NEWS] Hua Medicine and DKSH Hong Kong Expand Strategic Partnership to Advance Innovative Diabetes Solutions

Hua Medicine and DKSH Hong Kong announced the expansion of their strategic partnership to accelerate patient access to innovative drug therapies in Hong Kong. The partnership brings together Hua Medicine's expertise in metabolic disease drug development and DKSH's integrated market expansion capabilities to deliver long-term value and meaningful healthcare impact across the region.

Jun 09

2026

[News] Hua Medicine Advances Glucose Homeostasis Platform at ADA 2026, Showcasing Dorzagliatin's Potential Across Metabolic Disease

Hua Medicine ("the Company", stock code: 2552.HK) presented a series of breakthrough research findings on dorzagliatin (Trade name: 华堂宁®, HuaTangNing, Trade name in Hong Kong: MYHOMSIS®, 華領片®), the world’s first-in-class glucokinase activator (GKA), at the 86th Scientific Sessions of the American Diabetes Association (ADA).

May 20

2026

[News] Hua Medicine Will Present Research Results at the 2026 American Diabetes Association (ADA) Scientific Sessions

Hua Medicine ("the Company", stock code: 2552.HK) announced today that it will present a series of research results of dorzagliatin, the Company's global first-in-class glucokinase activator (GKA), at the 86th American Diabetes Association (ADA) Scientific Sessions.

Mar 27

2026

[News] Hua Medicine Announces 2025 Annual Results

Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the "Reporting Period").

Mar 03

2026

[News] Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.

Dec 09

2025

[News] Hua Medicine Initiated Phase Ib Clinical Trial of 2nd Gen GKA in the U.S. and Completed Enrollment of First Patient

Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced that the multiple-ascending dose (MAD) Phase Ib clinical trial of HMS1005 (formerly known as HM-002-1005), a second-generation glucokinase activator (GKA) independently developed by the Company, has successfully completed the first patient dosing in the United States.

About Us

Overview

Our History

Leadership Team

Portfolio Advisory Board

Partner

Media center

Research & Development

Inovation

Dorzagliatin

mGluR5

Presentations

Peer Reviewed Publications

Media

Company News

Media Releases

Video

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Careers

Culture

Join Us

Products&Pipeline

Pipeline

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.